TARO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	26 688.00
Średni wolumen	43 979.00
Kapitalizacja rynkowa	1.59B
EPS	$0 ( 2024-01-25 )
Następna data zysków	( $0.310 ) 2024-05-28
Last Dividend	$12.81 ( 2018-12-10 )
Next Dividend	$0 ( N/A )
P/E	34.75
ATR14	$0.0200 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Sell	712 500	Warrant (right to buy)
2010-11-04	Sun Pharmaceutical Industries Ltd	Buy	5 159 765	Ordinary Shares
2010-11-01	Franklin Resources Inc	Sell	5 159 765	Ordinary Shares

INSIDER POWER
0.00
Last 84 transactions
Buy: 16 575 249 \| Sell: 25 681 902

Wolumen Korelacja

Długi: 0.07 (neutral)

Krótki: -0.73 (moderate negative)

Signal:(41.437) Neutral

Taro Pharmaceutical Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Taro Pharmaceutical Korelacja - Waluta/Towar

0.69
( moderate )

0.88
( strong )

0.00
( neutral )

0.49
( neutral )

0.18
( neutral )

0.84
( strong )

Taro Pharmaceutical Finanse

Annual	2023
Przychody:	$572.95M
Zysk brutto:	$268.32M (46.83 %)
EPS:	$0.680

FY	2023
Przychody:	$572.95M
Zysk brutto:	$268.32M (46.83 %)
EPS:	$0.680

FY	2022
Przychody:	$561.35M
Zysk brutto:	$293.12M (52.22 %)
EPS:	$1.550

FY	2021
Przychody:	$548.97M
Zysk brutto:	$296.66M (54.04 %)
EPS:	$-10.12

Financial Reports:

No articles found.

Taro Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Taro Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.86 - average (62.51%) | Divividend Growth Potential Score: 2.19 - No dividend growth expected in the near future

Information

First Dividend	$12.81	2018-12-10
Last Dividend	$12.81	2018-12-10
Next Dividend	$0	N/A
Payout Date	2018-12-28
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.22	--
Div. Sustainability Score	5.86
Div.Growth Potential Score	2.19
Div. Directional Score	4.03	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.22

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$12.81	12.40%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0748	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0211	1.200	9.30	10.00	[0 - 0.3]
returnOnEquityTTM	0.0261	1.500	-0.821	-1.231	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.60	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.03	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.022	1.500	5.43	8.15	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.55	1.000	-2.05	-2.05	[3 - 30]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.29	2.00	8.86	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.480	1.000	5.33	5.33	[0.2 - 0.8]
operatingProfitMarginTTM	0.0360	1.000	-1.280	-1.280	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.451	-1.161	[0.5 - 2]
Total Score				5.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.87	1.000	6.58	0	[1 - 100]
returnOnEquityTTM	0.0261	2.50	-0.528	-1.231	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.29	2.00	9.24	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.769	1.500	-8.46	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.234	1.000	6.65	0	[0.1 - 0.5]
Total Score				2.19

Taro Pharmaceutical

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.